The INS News
No Result
View All Result
  • Home
  • News
    • Regional
    • Srinagar
    • Jammu
    • National
    • World
  • Business & Economy
  • Multimedia
    • Photo Gallery
    • Video Gallery
  • Health
  • Jobs & Careers
  • Press Releases
  • Blog
  • Home
  • News
    • Regional
    • Srinagar
    • Jammu
    • National
    • World
  • Business & Economy
  • Multimedia
    • Photo Gallery
    • Video Gallery
  • Health
  • Jobs & Careers
  • Press Releases
  • Blog
No Result
View All Result
The INS News
No Result
View All Result
Home News Regional

DAK seeks compulsory licensing for Covid-19 vaccine, drugs

INS Desk by INS Desk
May 10, 2021
A A
Decision to introduce rotavirus vaccines immensely important step: Atal Dulloo

Share on FacebookShare on TwitterWhatsappTelegramEmail

Srinagar, May 10: Doctors Association Kashmir (DAK) on Monday urged the Union government to grant compulsory license for Covid-19 vaccines and drugs.
“That would make vaccines and life-saving Covid medicines accessible to people and save lives,” said DAK President and influenza expert Dr Nisar ul Hassan.
“Compulsory licensing is a provision under the patent act that enables a government to allow other pharma companies to produce the patented drugs in times of public health emergency,” he said.
“A pharma company that develops a drug gets patent protection that prohibits other manufacturers from producing the drug for a period of 20 years,” he added.
Dr Hassan said we are in a grave public health crisis and precious lives are being lost each day. The lives of people should take priority over everything else.
“We should go for compulsory licensing now,” he said.
Dr Hassan said in order to respond to the huge demand for vaccines and drugs, there is a need to rapidly upscale production, which can only happen when there are more companies involved in manufacturing and this is possible by issuing compulsory licenses.
He said Tocilizumab, a life-saving drug for Covid is one of the patented drugs for which the government should invoke a compulsory licensing clause.
“The drug which costs Rs 40,000 for a single dose is manufactured by Switzerland based pharma company Roche and is marketed by Cipla in India. Despite being on clinical protocol, there is a shortage of the drug,” he added.
The DAK President said though the patent owner of Remdesivir Gilead, a US based Pharma Company has allowed few Indian pharma houses to produce the drug, there is an increased demand amid severe second wave of the pandemic and we need to permit others to manufacture the drug.
He said in order to reach herd immunity we need to vaccinate three in five and for that the country needs 150 to160 crore doses of the vaccine. And we need them quickly. Currently, India is producing 65 million doses every month,” he said.
“This makes a crying need for patent wavering and granting of compulsory licensing for other manufacturing units to produce the vaccine,” said Dr Nisar.

RELATED POSTS

AEJAK, ASMEA present memorandum of demands to LG Sinha

‘Operation Sindoor’ India’s biggest anti-terror success: PM Modi in Bhopal

Proper security in place for Kheer Bhawani mela: IGP Kashmir

Buy JNews
ADVERTISEMENT
Previous Post

KU extends last date for UG admissions till May 20

Next Post

Ensure 100 percent screening of passengers and travellers: Advisor Baseer Khan as he visits screening Kiosk at toll plaza Qazigund, Srinagar

INS Desk

INS Desk

Related Posts

AEJAK, ASMEA present memorandum of demands to LG Sinha
Regional

AEJAK, ASMEA present memorandum of demands to LG Sinha

May 31, 2025
J&K has immense opportunity in tourism sector: PM Modi
Regional

‘Operation Sindoor’ India’s biggest anti-terror success: PM Modi in Bhopal

May 31, 2025
Take stern action against those violating law: IGP
Regional

Proper security in place for Kheer Bhawani mela: IGP Kashmir

May 31, 2025
Weather to remain cloudy till Oct 28
Regional

MeT predicts rains, gusty winds today

May 31, 2025
Sonamarg—Zojila road closed for traffic after fresh snowfall
Regional

After fresh snowfall, Mughal Road closed for traffic

May 31, 2025
Sanjeev Verma is new CEO, J&K
Regional

Sanjeev Verma is new CEO, J&K

May 30, 2025
Next Post
Baseer Khan visits Ramban, reviews Yatra arrangements

Ensure 100 percent screening of passengers and travellers: Advisor Baseer Khan as he visits screening Kiosk at toll plaza Qazigund, Srinagar

Breaking the chain of transmission is key to containing the surge of positive cases: Dr Khurshid Ahmad Bhat

Breaking the chain of transmission is key to containing the surge of positive cases: Dr Khurshid Ahmad Bhat

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *




House of killed PDP worker set ablaze

Unknown persons damage property of alleged army informer in Shopian

June 12, 2018
No let up in operations against militants in Kashmir: Army chief

Chopper crash: 13 of 14 confirmed dead

December 8, 2021
3 IAS officers attached to H&ME for assisting in Coronavirus mitigation efforts in J&K

93 Fresh Covid-19 Cases, No Death Reported In Jammu and Kashmir

September 6, 2021

About

Indian News Service (INS) is the first registered online news portal from the state of Jammu & Kashmir. Our creative team consists of like-minded and socially concerned team of media professionals who carry decades of experience in their field of profession at their back. Our core values have pillars in honesty, empathy, credibility, equality and integrity.

More

© 2022 INS News - Designed by GITS.

No Result
View All Result
  • Home
  • News
    • Regional
    • Srinagar
    • Jammu
    • National
    • World
  • Business & Economy
  • Multimedia
    • Photo Gallery
    • Video Gallery
  • Health
  • Jobs & Careers
  • Press Releases
  • Blog

© 2022 INS News - Designed by GITS.